(ECAT) BlackRock ESG Capital - Ratings and Ratios
Stocks, Bonds, ETFs, REITs
ECAT EPS (Earnings per Share)
ECAT Revenue
Description: ECAT BlackRock ESG Capital
BlackRock ESG Capital Allocation Trust (NYSE:ECAT) is a closed-end fund that focuses on investing in a diversified portfolio of securities, with a particular emphasis on environmental, social, and governance (ESG) considerations. As a member of the Asset Management & Custody Banks sub-industry, ECATs performance is closely tied to the overall health of the asset management sector.
Key economic drivers for ECAT include the overall direction of the global financial markets, investor appetite for ESG-themed investments, and the competitive landscape within the asset management industry. The trusts investment strategy is likely influenced by the growing demand for sustainable investing and the increasing importance of ESG factors in investment decision-making.
To evaluate ECATs performance, relevant KPIs could include its net asset value (NAV) return, dividend yield, and ESG-themed investment holdings as a percentage of total assets under management. Additionally, metrics such as the trusts expense ratio, trading volume, and premium/discount to NAV could provide insight into its operational efficiency and market sentiment.
From a financial perspective, ECATs price-to-earnings (P/E) ratio of 7.00 suggests that the trust may be undervalued relative to its earnings. The return on equity (RoE) of 13.12 indicates that ECAT is generating strong returns for its shareholders. Further analysis of the trusts quarterly tax provision could provide insight into its tax planning strategies and potential risks associated with changes in tax laws or regulations.
Overall, a thorough analysis of ECAT would require a deep dive into its investment portfolio, management teams track record, and the competitive positioning of its parent company, BlackRock. By examining these factors, investors can gain a more comprehensive understanding of the trusts potential for long-term growth and returns.
ECAT Stock Overview
| Market Cap in USD | 1,650m |
| Sub-Industry | Asset Management & Custody Banks |
| IPO / Inception | 2021-09-28 |
ECAT Stock Ratings
| Growth Rating | 57.1% |
| Fundamental | 60.6% |
| Dividend Rating | 94.0% |
| Return 12m vs S&P 500 | -0.78% |
| Analyst Rating | - |
ECAT Dividends
| Dividend Yield 12m | 23.20% |
| Yield on Cost 5y | 29.77% |
| Annual Growth 5y | 131.28% |
| Payout Consistency | 80.0% |
| Payout Ratio | 120.7% |
ECAT Growth Ratios
| Growth Correlation 3m | 96.4% |
| Growth Correlation 12m | 67.9% |
| Growth Correlation 5y | 80.9% |
| CAGR 5y | 8.25% |
| CAGR/Max DD 5y | 0.26 |
| Sharpe Ratio 12m | 1.56 |
| Alpha | 3.93 |
| Beta | 0.716 |
| Volatility | 9.38% |
| Current Volume | 339.8k |
| Average Volume 20d | 381.5k |
| Stop Loss | 16 (-3.3%) |
| Signal | -1.46 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (240.6m TTM) > 0 and > 6% of Revenue (6% = 14.7m TTM) |
| FCFTA 0.18 (>2.0%) and ΔFCFTA 9.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.18 (>3.0%) and CFO 338.4m > Net Income 240.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| error: Current Ratio cannot be calculated (needs Total Current Assets and Liabilities) |
| Outstanding Shares last Quarter (101.9m) change vs 12m ago -0.48% (target <= -2.0% for YES) |
| Gross Margin 98.36% (prev 0.0%; Δ 98.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.47% (prev 14.68%; Δ -2.21pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.0 (EBITDA TTM 0.0 / Interest Expense TTM 1330 ) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 60.59
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 20.56% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC 0.0% = 0.0 |
| 7. RoE 13.12% = 1.09 |
| 8. Revenue Trend data missing |
| 9. Revenue CAGR data missing |
| 10. EPS Trend 100.0% = 2.50 |
| 11. EPS CAGR 1773 % = 2.50 |
What is the price of ECAT shares?
Over the past week, the price has changed by +0.24%, over one month by +3.05%, over three months by +10.88% and over the past year by +15.09%.
Is BlackRock ESG Capital a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ECAT is around 23.24 USD . This means that ECAT is currently undervalued and has a potential upside of +40.42% (Margin of Safety).
Is ECAT a buy, sell or hold?
What are the forecasts/targets for the ECAT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 26 | 56.8% |
Last update: 2025-08-25 04:35
ECAT Fundamental Data Overview
CCE Cash And Equivalents = 4.27m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 7.0084
P/S = 6.8937
P/B = 0.9457
Beta = None
Revenue TTM = 244.6m USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -4.27m USD (from netDebt column, last quarter)
Enterprise Value = 1.65b USD (1.65b + (null Debt) - CCE 4.27m)
Interest Coverage Ratio = 0.0 (Ebit TTM 0.0 / Interest Expense TTM 1330 )
FCF Yield = 20.56% (FCF TTM 338.4m / Enterprise Value 1.65b)
FCF Margin = 138.4% (FCF TTM 338.4m / Revenue TTM 244.6m)
Net Margin = 98.36% (Net Income TTM 240.6m / Revenue TTM 244.6m)
Gross Margin = 98.36% ((Revenue TTM 244.6m - Cost of Revenue TTM 4.01m) / Revenue TTM)
Tobins Q-Ratio = 0.94 (Enterprise Value 1.65b / Book Value Of Equity 1.74b)
Interest Expense / Debt = unknown (Interest Expense 1330 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets 4.27m / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt -4.27m / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 338.4m)
Total Stockholder Equity = 1.83b (last 4 quarters mean)
RoA = 12.69% (Net Income 240.6m, Total Assets 1.90b )
RoE = 13.12% (Net Income TTM 240.6m / Total Stockholder Equity 1.83b)
RoCE = unknown (Ebit 0.0 / (Equity 1.83b + L.T.Debt none))
RoIC = 0.0% (NOPAT 0.0 / Invested Capital 1.74b)
WACC = unknown (E(1.65b)/V(0.0) * Re(8.65%)) + (D(none)/V(0.0) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 5-Years: -94.90 | Cagr: -1.22%
Discount Rate = 8.65% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 79.50% ; FCFE base≈269.3m ; Y1≈332.2m ; Y5≈566.8m
Fair Price DCF = 86.42 (DCF Value 8.58b / Shares Outstanding 99.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 100.0 | EPS CAGR: 1773 %
EPS Growth-of-Growth: N/A
Additional Sources for ECAT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle